People: Achillion Pharmaceuticals Inc (ACHN.O)

ACHN.O on Nasdaq

11.06USD
22 Sep 2014
Price Change (% chg)

$-0.44 (-3.83%)
Prev Close
$11.50
Open
$11.43
Day's High
$11.49
Day's Low
$10.82
Volume
5,054,732
Avg. Vol
5,773,327
52-wk High
$13.80
52-wk Low
$2.26

Search Stocks

Apelian, David 

Brief Biography

Dr. David Apelian, M.D., Ph.D., MBA, has been appointed as Executive Vice President, Chief Medical Officer of Achillion Pharmaceuticals, Inc., effective May 28, 2013. Dr. Apelian brings to Achillion more than 13 years of industry experience from Bristol-Myers Squibb, Schering Plough and GlobeImmune where he focused on hepatology and infectious disease clinical development. Dr. Apelian was Clinical Director in the Infectious Diseases Group at Bristol-Myers Squibb (BMS), serving as medical co-lead for the clinical development and NDA submission of entecavir for chronic hepatitis B viral infection (HBV). Prior to BMS, Dr. Apelian served as Clinical Director in the Department of Hepatology/Gastroenterology at Schering Plough, coordinating a supplemental NDA filing for interferon alpha-2b and ribavirin for the treatment of pediatric patients with chronic hepatitis C viral infection (HCV). Most recently, Dr. Apelian served as Senior Vice President of Research and Development and Chief Medical Officer at GlobeImmune, where he was responsible for clinical development, regulatory affairs, clinical immunology, development of companion diagnostics, as well as target discovery and preclinical research. Dr. Apelian completed his residency training in Pediatrics at New York Hospital, Cornell Medical Center. He received his M.D. from the University of Medicine and Dentistry of New Jersey, and his Ph.D. in Biochemistry and B.A. from Rutgers University. He also holds an M.B.A. from Quinnipiac University.

Basic Compensation

Total Annual Compensation, USD Long-Term Incentive Plans, USD All Other, USD Fiscal Year Total, USD
356,767 -- 1,818,360 2,175,130

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Scheer

--

Milind Deshpande

4,853,430

Mary Kay Fenton

989,616

Gautam Shah

883,243

David Apelian

2,175,130

Joseph Truitt

886,617
As Of 30 Dec 2013
Search Stocks